Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market to Reach $3.3 Billion by 2024 - Rising Prevalence of Infectious Diseases and Introduction of Newer Pathogens Drives Growth
DUBLIN, Jan. 27, 2020 /PRNewswire/ -- The "Isothermal Nucleic Acid Amplification Technology/INAAT Market by Product (Assay & Kit, System), Application (Infectious disease [HIV, Influenza], Blood Screening), Type (LAMP, SDA, NASBA, HDA), End User, Region - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.
The global isothermal nucleic acid amplification technology (INAAT) market size is expected to grow from USD 1.9 billion in 2019 to USD 3.3 billion by 2024, at a CAGR of 11% during the forecast period.
The major factors driving the growth of this market include the rising prevalence of infectious diseases and the introduction of newer pathogens, the need for prompt diagnosis, the increasing number of blood transfusions and donations, and the cost-benefits of INAAT. However, the extensive usage and reliance on PCR are expected to limit the adoption of INAAT.
The INAAT market comprises major players such as Grifols S.A. (Spain), Hologic, Inc. (US), Abbott Laboratories, Inc. (US), Becton, Dickinson & Company (US), and Meridian Bioscience (US). The study includes an in-depth competitive analysis of these key players in the INAAT market, along with their company profiles, recent developments, and key market strategies.
Assay, kits and reagents segment is expected to grow at the highest CAGR during the forecast period.
Based on the product, the market is segmented broadly into assay, kits, and reagents, and systems. The assay, kits, and reagents segment is projected to grow at the highest CAGR during the forecast period. The increasing number of infectious disease diagnostic tests carried out; the rising prevalence of infectious diseases; the continuous launch of newer, faster, and more reliable POC products; increasing approvals of CLIA-waived tests; accessibility to a wide range of reagents; repeated purchase of reagents; and the increasing use of reagents in therapeutics, basic research, and assay development.
TMA is expected to grow at CAGR during the forecast period.
Based on type, the INAAT market is segmented into TMA, LAMP, SDA, HDA, NASBA, and other INAAT technologies. The TMA segment is expected to be the fastest-growing segment during the forecast period due to the growing reliance on POC diagnosis in hospitals and blood banks.
Infectious disease diagnosis segment to grow at the highest CAGR during the forecast period.
The INAAT market, by the applications, has been categorized into infectious disease diagnosis, blood screening, and other applications (cancer diagnosis, cancer research, and laboratory research, which encompass cDNA preparation, whole-genome amplification (WGA), single-nucleotide polymorphism (SNP), and mutation analysis). Infectious disease diagnosis segment to grow at the highest CAGR during the forecast period owing to the increasing number of infectious disease diagnostic tests carried out and rising prevalence of infectious diseases, among others.
Asia-Pacific expected to account for the largest share of the global INAAT market in 2019.
Asia-Pacific is expected to be the fastest-growing segment during the forecast period. Factors such as the sustained economic growth in several Asia Pacific countries, the rising disposable income, healthcare infrastructure modernization, increasing penetration of cutting-edge diagnostic technologies (including INAAT) for research and clinical applications, high infectious disease burden, availability of low-cost POC INAAT assays, and growing awareness among physicians and healthcare professionals about the benefits of gene-based disease diagnosis and treatment in Asia Pacific countries are expected to support market growth in this region during the forecast period.
Key Topics Covered
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 Isothermal Nucleic Acid Amplification Technology Market Overview
4.2 North America: Isothermal Nucleic Acid Amplification Technology Market Share, By Product & Country (2019)
4.3 Isothermal Nucleic Acid Amplification Technology Market, By End User
4.4 Isothermal Nucleic Acid Amplification Technology Market, By Application
4.5 Isothermal Nucleic Acid Amplification Technology Market, By Type
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Rising Prevalence of Infectious Diseases and the Introduction of Newer Pathogens
5.2.1.2 Need for Prompt Diagnosis and Rapid Treatment
5.2.1.3 Increasing Blood Transfusion and Donations
5.2.1.4 Cost-Benefits
5.2.2 Restraint
5.2.2.1 Dominance of PCR
5.2.3 Opportunities
5.2.3.1 Technology Optimization and Development
5.2.3.2 Emerging Economies
6 Isothermal Nucleic Acid Amplification Technology Market, By Product
6.1 Introduction
6.2 Assays, Kits, and Reagents
6.2.1 Assays, Kits, & Reagents Accounted for the Largest Share of the Market in 2018
6.3 Systems
6.3.1 Market for Systems to Witness Steady Growth Due to Moderate Requirement in Hospitals and Clinical Laboratories
7 Isothermal Nucleic Acid Amplification Technology Market, By Type
7.1 Introduction
7.2 Transcription-Mediated Amplification
7.2.1 Tma Accounts for the Largest Share of the Market
7.3 Loop-Mediated Isothermal Amplification
7.3.1 Rapidity, Stability, and Sensitivity Have Driven the Use of Lamp
7.4 Strand Displacement Amplification
7.4.1 Mirna Amplification for Cancer Diagnosis is the Major Application of Sda
7.5 Helicase-Dependent Amplification
7.5.1 Compatibility With Microfluidic Technologies & Development of Lab-On-Chip Devices Support Market Growth in Hda
7.6 Nucleic Acid Sequence-Based Amplification
7.6.1 Advantages of Nasba Over Pcr has Enhanced Its Adoption in Clinical Settings
7.7 Other Technologies
8 Isothermal Nucleic Acid Amplification Technology Market, By Application
8.1 Introduction
8.2 Infectious Disease Diagnosis
8.2.1 Hepatitis
8.2.1.1 Need to Combat the High Prevalence of Hepatitis has Raised the Demand for INAAT Assays
8.2.2 Ct/Ng
8.2.2.1 Adoption of INAAT for Ct/Ng Diagnosis is Growing Owing to Its Advantages Over Traditional Diagnostic Techniques
8.2.3 Hiv
8.2.3.1 New Product Development Will Provide Considerable Potential for Growth in the Near Future
8.2.4 Influenza
8.2.4.1 Nasba, Lamp, and Samba are Considered Highly Efficient and Reliable Methods of Influenza Diagnosis
8.2.5 Other Infectious Diseases
8.3 Blood Screening
8.3.1 Increasing Number of Blood Donations and Transfusions Have Driven the Use of INAAT in Blood Screening Applications
8.4 Other Applications
9 Isothermal Nucleic Acid Amplification Technology Market, By End User
9.1 Introduction
9.2 Hospitals
9.2.1 Hospitals Formed the Largest End-User Segment in the INAAT Market in 2018
9.3 Reference Laboratories
9.3.1 Outsourcing of Tests From Small Hospitals, Physicians' Offices, and Clinics to Support the Growth of This End-User Segment
9.4 Academic & Research Institutes
9.4.1 Industry-Academia Collaborations Supporting the Adoption of INAAT
9.5 Other End Users
10 Isothermal Nucleic Acid Amplification Technology Market, By Region
10.1 Introduction
10.2 North America
10.2.1 US
10.2.1.1 US is A Well-Developed Market for Genome Analysis Techniques
10.2.2 Canada
10.2.2.1 Investments for Genomic Research and Development of Diagnostics are Supporting Market Growth in Canada
10.3 Europe
10.3.1 Germany
10.3.1.1 Germany Dominated the European INAAT Market in 2018
10.3.2 France
10.3.2.1 Supportive Government Policies That Aim to Ease Public Access to Diagnostic Assay Procedures to Drive Growth in the INAAT Market
10.3.3 UK
10.3.3.1 Adoption of INAAT Products is Expected to Increase in the UK as A Result of the Growing Focus of Public and Private Organizations on Genomics Research
10.3.4 RoE
10.4 Asia Pacific
10.4.1 Asia Pacific to Offer Significant Growth Opportunities for INAAT Market Players
10.5 RoW
10.5.1 The RoW INAAT Market is Significantly Smaller Than Other Markets
11 Competitive Landscape
11.1 Introduction
11.2 Market Ranking Analysis, 2018
11.3 Competitive Leadership Mapping
11.3.1 Visionary Leaders
11.3.2 Innovators
11.3.3 Dynamic Differentiators
11.3.4 Emerging Companies
11.4 Competitive Scenario
11.4.1 Key Product Launches
11.4.2 Key Acquisitions
11.4.3 Key Partnerships, Agreements, Contracts, and Collaborations
11.4.4 Key Expansions
12 Company Profiles
12.1 Grifols, S.A.
12.1.1 Business Overview
12.1.2 Products Offered
12.1.3 Recent Developments
12.2 Hologic, Inc.
12.3 Abbott Laboratories, Inc.
12.4 Becton, Dickinson and Company
12.5 Meridian Bioscience
12.6 Eiken Chemicals Co. Ltd.
12.7 Quidel Corporation
12.8 Tecan Trading AG
12.9 Diasorin Group S.P.A
12.10 Qiagen
12.11 Illumina, Inc.
12.12 Thermo Fisher Scientific, Inc.
12.13 bioMerieux S.A.
12.14 GE Healthcare
12.15 Other Companies
12.15.1 New England Biolabs, Inc.
12.15.2 Lucigen Corporation
12.15.3 Ustar Biotechnologies Ltd.
12.15.4 TwistDx Limited
12.15.5 Mast Group Ltd.
12.15.6 Genomtec S.A.
For more information about this report visit https://www.researchandmarkets.com/r/uxhr3z
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article